More LEADER: Liraglutide Delays Progression of Renal Events More LEADER: Liraglutide Delays Progression of Renal Events

Nephropathy results from the LEADER trial show that liraglutide reduces renal events by 22% compared with placebo, mainly driven by reduction in new-onset macroalbuminuria.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news